Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab plus multimodal therapy versus multimodal therapy alone in locally advanced esophageal carcinoma
2009-016584-10Phase 3Completed
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Apr 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of cetuximab in esophageal cancer, Esophageal Squamous Cell Carcinoma (ESCC), esophageal adenocarcinoma (EAC) and 1 more (2 arms), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Progression-free survival. Started Apr 2010; status: completed.
02
Drugs
cetuximab
03
Conditions
esophageal cancerEsophageal Squamous Cell Carcinoma (ESCC)esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2009-016584-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016584-10.